Latest Advances in Precision Oncology: Scientific Review

Zenocutuzumab Earns FDA Priority Review for NRG1+ NSCLC and Pancreatic Cancer

Zenocutuzumab, a bispecific antibody, has received FDA priority review for NRG1 fusion-positive non-small cell lung cancer (NSCLC) and pancreatic cancer. This decision is based on promising phase 1/2 eNRGy trial data. Learn more about this significant development.

Read the article

FDA oncologydrug decisions coming soon

In June 2024, the FDA will decide on tarlatamab for advanced small-cell lung cancer (SCLC) and imetelstat for lower-risk myelodysplastic syndromes (MDS). Early trials show promising results for both therapies, which could significantly impact treatment options.

Read the article

New treatments for Non-Small Cell Lung Cancer (NSCLC)

This article provides a comprehensive review of current first-line treatments for non-small cell lung cancer (NSCLC) without oncogenic alterations, focusing on immune checkpoint inhibitors (ICIs), combination treatments, and emerging therapies. It discusses strategies for PD-L1 high expressers, dual checkpoint blockade, and future approaches like antibody-drug conjugates.

Read the article

FDA-Approved AI Algorithm Reveals Bias in Mammogram Screening

A study found that an FDA-approved AI algorithm used in mammogram screenings shows higher false positive rates for African-American and older women compared to White and younger patients. This discrepancy highlights the need for more diverse training datasets to ensure AI tools are effective across all demographics.

Read the article

News / Events

Festival Of Genomics January 2025

Jan 10th

We help you navigate a complex genomics ecosytem OncoDNA understands the complexities of the personalized medicine ecosystem and leverages over 10 years of expertise in genomic profiling to guide laboratories and oncologists in their use...

Video

Voice Of Customer – Episode 2

Dec 9th

In this episode, Pr. Daniela Cesselli (University of Udine) discusses the strategic needs that drove the adoption of a CGP panel and the reasons behind choosing the 𝗢𝗻𝗰𝗼𝗗𝗘𝗘𝗣® 𝗞𝗶𝘁 solution. Was it to ensure timely...

Webinar

Webinar : Comprehensive Genomic Profiling: What’s the Business Case? Hear the experience of an existing OncoDEEP® Kit customer

Nov 14th

Is Comprehensive Genomic Profiling right for your lab? Download the webinar replay: Comprehensive Genomic Profiling: What’s the Business Case? Hear the experience of an existing OncoDEEP® Kit customer Wednesday, December 11, 20244:00 PM CET By...

Scientific Review: latest discoveries in precision oncology

Zenocutuzumab Earns FDA Priority Review for NRG1+ NSCLC and Pancreatic Cancer

FDA oncologydrug decisions coming soon

New treatments for Non-Small Cell Lung Cancer (NSCLC)

FDA-Approved AI Algorithm Reveals Bias in Mammogram Screening

You may also be interested in these resources

Festival Of Genomics January 2025

Voice Of Customer – Episode 2

Webinar : Comprehensive Genomic Profiling: What’s the Business Case? Hear the experience of an existing OncoDEEP® Kit customer